Another recent systematic review of 1 RCT and 3 controlled nonrandomized studies of CP therapy in patients with COVID-19 reported a potential reduction in mortality, time to death, and improvement of clinical symptoms but was unable to provide any opinion regarding the efficacy of CP treatment for COVID-19 due to paucity in quantitative synthesis [207]. The gene discussed is CP; the disease is COVID-19.